Brief: Sol-Gel Technologies Announces FDA Acceptance For Filing Of New Drug Application For Epsolay
10/09/2020 21:10
Sept 10 (Reuters) - Sol Gel Technologies Ltd SLGL.O :
* SOL-GEL TECHNOLOGIES ANNOUNCES FDA ACCEPTANCE FOR FILING
OF NEW
DRUG APPLICATION FOR EPSOLAY® FOR THE TREATMENT OF INFLAMMATORY
LESIONS OF ROSACEA
* SOL GEL TECHNOLOGIES LTD - PDUFA GOAL DATE SET FOR APRIL
26,
2021
Source text for Eikon: ID:nGNX1xQbD3
Further company coverage: SLGL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SOL-GEL TECHNOLOGIES
See all newsIsraeli dermatology firm Sol-Gel's Q2 revenue drops sharply on prior-year IP sale
SOL-GEL TECHNOLOGIES LTD. expected to post a loss of $2.57 a share - Earnings Preview
Sol-Gel Q1 revenue falls sharply on milestone payment impact
Brief: Sol-Gel Technologies Ltd. Q1 Revenue USD 100 Thousand
Brief: Sol-Gel Technologies Ltd. Announces Pricing Of Oversubscribed Underwritten Offering